FDA Issues CRL for Ivonescimab BLA
FDA Issues CRL for Ivonescimab BLA
Conclusion: The FDA's Complete Response Letter (CRL) on ivonescimab is a direct hit to Summit, not a spillover from Akeso. Summit holds the U.S. BLA, and Akeso is the Chinese originator that licensed most rights to Summit in 2022. Both stocks repriced the same asset. Summit closed at on Monday, Nov 16, 2026, down from . The U.S. first-approval path for ivonescimab in this setting is closed for now. The bigger value drivers are the first-line Phase 3 readouts (HARMONi-3) and whether the company can re-open the regulatory path, not the EGFR-mutated filing itself.
Data as of: Quote is the regular-session close on Nov 16, 2026 (16:00 ET, NASDAQ). Filing and news context runs through Nov 16, 2026. Current time is Nov 17, 2026, 08:56 Asia/Shanghai.
What happened
- The FDA issued a CRL on the BLA for ivonescimab plus platinum chemotherapy in previously EGFR-TKI-treated, EGFR-mutated NSCLC. Summit announced it on Nov 15 (Summit press release).
- The FDA's reasoning: substantial evidence of effectiveness was not shown without a statistically significant overall survival (OS) improvement. A progression-free survival (PFS) benefit alone did not support a positive benefit-risk profile (Summit press release).
- The OS data were the problem. In the global HARMONi trial's primary OS analysis, the Western-subgroup hazard ratio was , per Fierce Pharma. Summit's later post-hoc data cut showed in the Western cohort, but the FDA did not accept it.
- The trade pattern was consistent with a known risk. Summit fell on Friday ahead of the decision, then fell about on Monday per BioPharma Dive. The structured quote shows the full Monday move at -16.47%, so I use that figure.
The Akeso connection
- Akeso (Hong Kong-listed) traded first, because Hong Kong opened before the U.S. session. Its shares fell on Monday, per BioPharma Dive.
- Summit then repriced during the U.S. session on the same news. Akeso's drop was not the cause of Summit's drop. Both reflect the market's assessment of one asset, with Summit owning the U.S. commercial and regulatory right.
- Pre-decision expectations were already low. Leerink had assigned a approval probability on Nov 5 (Fierce Pharma). TD Cowen called the outcome consistent with the "high bar FDA had previously communicated" (BioPharma Dive).
Development implications
- The EGFR-mutated U.S. launch is delayed. Summit's first U.S. approval target is gone. Any re-filing would likely need a statistically significant OS result. Neither the company nor the articles describe a resubmission timeline. Treat that as an open question.
- China data have limited read-through. Leerink noted Summit may not be able to rely on China-only HARMONi-6 results to support lung cancer filings in other settings (BioPharma Dive). This narrows the regulatory path for other lung indications.
- The first-line program is now the main test. HARMONi-3 is the key readout. The squamous cohort moves to a final PFS analysis by year-end 2026. The non-squamous cohort could report PFS in 1H 2027 (Fierce Pharma). An April interim analysis of the squamous cohort missed statistical significance on PFS, so this is a known weak point.
- Balance sheet is not the immediate constraint. Weeks before the decision, Summit secured a cash injection from AstraZeneca, per Fierce Pharma. That funds the trials that remain.
Regulatory and competitive risks
- FDA standard: The FDA has now shown it will not accept PFS plus a non-significant OS trend in this setting. That raises the bar for other indications.
- Competition in the PD-(L)1×VEGF class: The rejection narrows Summit's first-mover advantage. Pfizer/3SBio, BioNTech/BMS, Merck, and AbbVie are moving their own bispecifics into global Phase 3 trials (Fierce Pharma).
- Commercial readiness: Summit parted ways with its chief commercial officer and several senior commercial leaders before the decision (Fierce Pharma). That may need to be rebuilt depending on the timing of any future approval.
- Safety: Treatment-related discontinuations were 7.3% for ivonescimab plus chemo versus 5.0% for placebo plus chemo. Four deaths were attributed to treatment in the ivonescimab arm. This did not drive the CRL, but it is part of the benefit-risk picture (Summit press release).
What would change the view
- Negative: HARMONi-3 squamous PFS misses at year-end, or the non-squamous readout in 1H 2027 disappoints. Either would hit the core value of the program more than this CRL.
- Positive: A clean first-line win would show the class works outside the EGFR-mutated setting, which is the real value driver. The CRL does not directly change that.
- Watch: Any FDA commentary on a resubmission path or whether the OS requirement is interpreted more flexibly for other indications.
Bottom line: The CRL removes a near-term U.S. approval and weakens the China-data read-through. The stock's medium-term value rests on first-line data that are still ahead. The -16.47% move is a reasonable first-order repricing of the lost EGFR-mutated launch, but it does not by itself establish the long-term value of the first-line program.